Dual-energy X-ray absorptiometry in the early diagnosis of body shape changes in patients with HIV infection treated with nucleoside reverse transcriptase inhibitors and naive to protease inhibitors
A. Cirelli et al., Dual-energy X-ray absorptiometry in the early diagnosis of body shape changes in patients with HIV infection treated with nucleoside reverse transcriptase inhibitors and naive to protease inhibitors, CURR THER R, 62(5), 2001, pp. 386-393
Citations number
18
Categorie Soggetti
Pharmacology,"Pharmacology & Toxicology
Journal title
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
Background: Antiretroviral therapies based on 2 nucleoside reverse transcri
ptase inhibitors (NRTIs) in combination with protease inhibitors (PIs) have
been shown to increase CD4 T-cell counts and induce clinical improvement i
n HIV-infected patients, with plasma virus suppression. PIs, however, may i
nduce hyperlipidemia, insulin resistance, fat redistribution, and lipoatrop
hy. It has been suggested that lipoatrophy and fat redistribution may also
occur in PI-naive patients treated with NRTIs.
Objective: The aim of this study was to evaluate body composition alteratio
ns in HIV-infected patients at various stages of the disease using dual-ene
rgy x-ray absorptiometry (DEXA).
Methods: Fat total, lean total, and bone mineral density of the whole body
and subregions (limbs and trunk), as assessed by DEXA analysis of body comp
osition, were compared between a group of HIV-infected patients and a contr
ol group matched for age, sex, and height.
Results: Twenty-five white male patients (mean age, 38.48 years) were enrol
led; 23 had been treated with NRTIs but not with PIs. DEXA analysis showed
a significant loss of subcutaneous adipose mass in the limbs and trunk in t
he HIV-infected group (P less than or equal to 0.013 vs control group), wit
hout any other metabolic or hematologic abnormalities. Lean total and bone
mineral density were not significantly different in the 2 groups.
Conclusions: Thinning of the extremities without metabolic changes or fat r
edistribution may indicate an initial lipoatrophy in those patients treated
with NRTIs; DEXA is an effective way to reveal and quantify these body cha
nges at an early stage.